UCSF

ZINC00538564

Substance Information

In ZINC since Heavy atoms Benign functionality
September 27th, 2005 29 Yes

Other Names:

(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide

(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; BICALUTAMIDE; BRN 5364666; Bicalutamide [USAN:INN:BAN]; C18H14F4N2O4S; CASODEX; ICI 176334; ICI-176334; LS-119125; Propanamide, N-(4-cyano-3-(trifluoromethyl

(2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide

(R)-Bicalutamide

(R)-N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide

(S)-Bicalutamide

Bicalutamide

lutamide

4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide

90357-06-5

90357-06-5; Bicalutamide (JAN/USP/INN); Casodex (TN); D00961

90357-06-5; Bicalutamide; C08160

AC-4232

AC1L1DJE

Astra brand of bicalutamide

AstraZeneca brand of bicalutamide

bicalutamida; bicalutamide; bicalutamidum

Bicalutamide

Bicalutamide (BAN

Bicalutamide (Casodex)

Bicalutamide (JAN/USP/INN)

Bicalutamide [USAN:INN:BAN]

Bicalutamide-d4

BICALUTAMIDE; CPD000466329; SAM001246612

BRN 5364666

C053541

C08160

C18H14F4N2O4S

Calutide

Casodex

Casodex (TN)

Casodex, Cosudex, Calutide, Kalumid, Bicalutamide

Casodex

CHEMBL409

CID2375

Cosudex

CPD000466329

CPD000466329; BICALUTAMIDE

D00961

DAP000092

DB01128

FDA

FT-0080576

HMS2051B13

HMS2089N12

I06-0475

I06-0480

ICI 176334

ICI-176334

INN

INN)

Kalumid

KS-1161

LS-119125

MFCD00869971

MFCD00870866

MFCD08063408

MLS000759437

MLS001424047

MolPort-003-845-034

MolPort-006-808-679

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide

N/A

NCGC00167977-01

NCGC00167977-02

NSC722665

Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-

Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-

Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,

propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-)

Raffolutil

S1190_Selleck

SAM001246612

SMR000466329

ST-7244

TL8005814

USAN

USAN)

Zeneca brand of bicalutamide

Download: MOL2 SDF SMILES Flexibase

Annotations

Vendors

Physical Representations

Type pH range xlogP Des A‑Pol Apolar desolvation (kcal/mol) Des Pol Polar desolvation (kcal/mol) H Don H-bond donors H Acc H-bond acceptors Chg Net charge tPSA (Ų) MWT Molecular weight (g/mol) RB Rotatable bonds DL
Ref Reference (pH 7) 2.15 4.05 -16.95 2 6 0 107 430.379 6

Vendor Notes

Note Type Comments Provided By
ALOGPS_SOLUBILITY 9.28e-03 g/l DrugBank-approved
Target Androgen Receptor, P450 Selleck Chemicals
mechanism Antiandrogen IBScreen Bioactives
biological_use Antiandrogen investigated for the treatment of advanced prostate cancer ZereneX Building Blocks
mechanism Antiandrogen ZereneX Building Blocks
Therapy antineoplastic SMDC Iconix
Patent Database Links EP1364659; EP1550720; EP1719527; EP1738759; EP1767533; EP1772452; EP1803454; EP1808163; EP1813609; EP1832576; EP1889610; EP1988098; US2001020038; US2004063782; US2004254182; US2005009845; US2005020675; US2005049263; US2005101646; US2005124614; US200512462 ChEBI
PUBCHEM_SUBSTANCE_COMMENT NCC_SAMPLE_SUPPLIER : Sequoia Research Products Ltd.; NCC_SUPPLIER_STRUCTURE_ID : SRP02002b NIH Clinical Collection via PubChem
mechanism Prevent the action of androgens by blocking the receptors for androgens on the cells of tissues, for example, the cells of the prostate gland IBScreen Bioactives
Indications prostate cancer KeyOrganics Bioactives
Indications prostate cancer, hirsutism KeyOrganics Bioactives
PUBCHEM_SUBSTANCE_COMMENT SAMPLE_SUPPLIER: Sequoia Research Products Ltd.; SUPPLIER_STRUCTURE_ID: SRP02002b NIH Clinical Collection via PubChem

Activity (Go SEA)

Clustered Target Annotations
Code Description Organism Class Affinity (nM) LE (kcal/mol/atom) Type
ANDR-4-E Androgen Receptor (cluster #4 Of 4), Eukaryotic Eukaryotes 11 0.38 Binding ≤ 10μM
ANDR-4-E Androgen Receptor (cluster #4 Of 4), Eukaryotic Eukaryotes 670 0.30 Binding ≤ 10μM
PRGR-2-E Progesterone Receptor (cluster #2 Of 3), Eukaryotic Eukaryotes 7200 0.25 Binding ≤ 10μM
Q5EM59-1-E Androgen Receptor (cluster #1 Of 1), Eukaryotic Eukaryotes 940 0.29 Binding ≤ 10μM
ANDR-3-E Androgen Receptor (cluster #3 Of 3), Eukaryotic Eukaryotes 270 0.32 Functional ≤ 10μM
ANDR-3-E Androgen Receptor (cluster #3 Of 3), Eukaryotic Eukaryotes 890 0.29 Functional ≤ 10μM
PRGR-1-E Progesterone Receptor (cluster #1 Of 2), Eukaryotic Eukaryotes 1819 0.28 Functional ≤ 10μM
Z80243-1-O MDA-MB-453 (Breast Adenocarcinoma Cells) (cluster #1 Of 1), Other Other 173 0.33 Functional ≤ 10μM
Z81170-1-O LNCaP (Prostate Carcinoma) (cluster #1 Of 5), Other Other 870 0.29 Functional ≤ 10μM
Z81170-1-O LNCaP (Prostate Carcinoma) (cluster #1 Of 5), Other Other 1000 0.29 Functional ≤ 10μM
ChEMBL Target Annotations
Uniprot Swissprot Description Affinity (nM) LE (kcal/mol/atom) Type
ANDR_HUMAN P10275 Androgen Receptor, Human 117 0.33 Binding ≤ 1μM
Q5EM59_BOVIN Q5EM59 Androgen Receptor, Bovin 940 0.29 Binding ≤ 1μM
ANDR_MOUSE P19091 Androgen Receptor, Mouse 670 0.30 Binding ≤ 1μM
ANDR_RAT P15207 Androgen Receptor, Rat 14 0.38 Binding ≤ 1μM
Q5EM59_BOVIN Q5EM59 Androgen Receptor, Bovin 940 0.29 Binding ≤ 10μM
ANDR_MOUSE P19091 Androgen Receptor, Mouse 670 0.30 Binding ≤ 10μM
ANDR_RAT P15207 Androgen Receptor, Rat 1300 0.28 Binding ≤ 10μM
ANDR_HUMAN P10275 Androgen Receptor, Human 117 0.33 Binding ≤ 10μM
PRGR_RAT Q63449 Progesterone Receptor, Rat 7200 0.25 Binding ≤ 10μM
PRGR_RABIT P06186 Progesterone Receptor, Rabit 5600 0.25 Binding ≤ 10μM
ANDR_HUMAN P10275 Androgen Receptor, Human 140 0.33 Functional ≤ 10μM
Z81170 Z81170 LNCaP (Prostate Carcinoma) 1000 0.29 Functional ≤ 10μM
Z80243 Z80243 MDA-MB-453 (Breast Adenocarcinoma Cells) 173 0.33 Functional ≤ 10μM
PRGR_HUMAN P06401 Progesterone Receptor, Human 1819 0.28 Functional ≤ 10μM

Reactome Annotations from Targets (via Uniprot)

Description Species
Nuclear Receptor transcription pathway
Nuclear signaling by ERBB4

Analogs ( Draw Identity 99% 90% 80% 70% )